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Background: Bevacizumab (B) and cetuximab (C) are both approved for use in the treatment of metastatic
colorectal cancer (mCRC) in the second-line. We examined patient reported symptom burden during second-line
treatment of mCRC.
Methods: Adult mCRC patients treated in the second-line setting with a regimen that included B, C, or
chemotherapy only (O) and who had completed≥ 1 Patient Care Monitor (PCM) surveys as part of routine clinical
care were drawn from the ACORN Data Warehouse. Primary endpoints were rash, dry skin, itching, nail changes,
nausea, vomiting, fatigue, burning in hands/feet, and diarrhea. Linear mixed models examined change in PCM
scores across B, C and O (B = reference).
Results: 182 patients were enrolled (B: n = 106, C: n = 38, O: n = 38). Patients were 51% female, 67% Caucasian, with
mean age of 62.0 (SD = 12.6). Groups did not differ on demographic or clinical characteristics. The most common
second-line regimens were FOLFIRI ± B or C (23.1%) and FOLFOX± B or C (22.5%). Results showed baseline scores to
be strongly predictive of second-line symptoms across all PCM items (all p’s < .0001 except for Rash, p = .0013).
Controlling for baseline, patients on B tended to have more stable and less severe symptoms. Patients on C had
more severe rash, dry skin, and itching and had nail change scores that worsened faster than did B patients.
Conclusions: Patients receiving second-line treatment for mCRC with B report less symptom burden, especially
dermatologic, compared to patients treated with C.
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The American Cancer Society estimates that approxi-
mately 141,210 people will be diagnosed with colorectal
cancer (CRC) in the United States in 2011 with roughly
49,380 people dying of the disease during the same time
frame [1]. CRC is the third most commonly diagnosed
cancer among both men and women and the third lead-
ing cause of cancer death overall. Incidence and death
rates for CRC increase with age with 90% of new cases
and 94% of deaths occurring in individuals 50 years of
age and older [1].* Correspondence: mwalker@acorncro.com
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reproduction in any medium, provided the orCRC is a cancer that starts in the large intestine or the
rectum. Cancer cells eventually spread to nearby lymph
nodes and subsequently to more remote lymph nodes
and other organs in the body with the liver and lungs
being the most common metastatic sites. Approximately
30% of all patients with CRC have metastatic disease at
diagnosis, and between 40% and 65% of all patients diag-
nosed with CRC will eventually develop metastatic or
advanced disease [2,3].
The management of patients with metastatic colorectal
cancer (mCRC) has changed dramatically over the last
decade. Historically, 5-fluorouracil (5-FU) was the only
active agent in CRC. The introduction of several new
chemotherapeutic (irinotecan, oxaliplatin) and biologic
agents (cetuximab, bevacizumab, panitumumab) intoLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sponse rates and overall survival [4–6].
The therapies recommended by the National Com-
prehensive Cancer Network (NCCN) after the first
progression in patients who have received prior 5-FU/
leucovorin (LV) based or capecitabine based therapies
are dependent on the initial treatment regimen [7,8].
If FOLFOX or CapeOx based therapies are used as
first-line, FOLFIRI, with or without cetuximab or panitu-
mumab (KRAS wild type tumor only), and irinotecan in
combination with cetuximab (KRAS wild type tumor
only) or as a single agent is recommended. In patients
who received a FOLFIRI based regimen as the first-line
therapy, FOLFOX or CapeOx, cetuximab plus irinotecan,
or single agent cetuximab or panitumumab (for those
not appropriate for the combination with irinotecan)
are recommended options. For patients who received
5-FU/LV or capecitabine without oxaliplatin or irino-
tecan as initial therapy, options after first progression
include FOLFOX, CapeOx, FOLFIRI, single agent irinote-
can, or irinotecan plus oxaliplatin. For patients who
received FOLFOXIRI as initial therapy, cetuximab plus iri-
notecan or cetuximab or panitumumab alone are recom-
mended options for those with wild-type KRAS gene.
NCCN guidelines also note that bevacizumab, if not used
in initial therapy, may be appropriate to add to chemo-
therapy following progression of metastatic disease.
Treatments for mCRC are mainly palliative. They seek
to increase the duration, and maintain or improve the
quality of the patient’s remaining life, a difficult task
given the toxicity of the given chemotherapy combina-
tions [5]. The addition of bevacizumab or cetuximab to
these regimens may result in somewhat different toxicity
profiles. Package inserts for both products report that
common reactions include headache and diarrhea [9,10].
Bevacizumab labeling also reports epistaxis (nosebleed),
hypertension, rhinitis, proteinuria, taste alteration, dry
skin, rectal hemorrhage, lacrimation disorder, back pain
and exfoliative dermatitis to occur in≥ 10% of cases [10].
Cetuximab labeling reports rash, pruritus, nail changes
and infection to occur in≥ 25% of cases [9].
Research has suggested health-related quality of life
(HRQoL) is positively associated with subsequent sur-
vival duration [11–13], making it an important consider-
ation in decisions related to treatment of patients with
metastatic disease. The total number of side effects and
the intensity of specific toxicities, most notably fatigue,
insomnia, nausea, vomiting and diarrhea, have been
shown to markedly affect patient satisfaction with
HRQoL [14–17]. The specific effect of other toxicities,
such as dermatologic toxicities, on patient satisfaction
with HRQoL is less well understood although they are
known to occur with frequency in some treatments
[18,19].Although many studies have examined HRQoL among
patients receiving first-line treatment of mCRC [20–22],
few have examined symptom burden and HRQoL in the
second-line. In the few that have, all have been conducted
in the clinical trial setting. In addition, few studies have
conducted multi-regimen comparisons involving recom-
mended therapies. The goal of the current study was to
describe symptom burden among patients treated for
mCRC in community settings who received second-line
regimens that contained (1) bevacizumab, (2) cetuximab
or (3) chemotherapy regimens without the addition of a
monoclonal antibody (designated Chemotherapy Only).
Materials and methods
Patients & setting
Potentially eligible patients were identified through re-
view of electronic records of patients at community
oncology practices represented in the ACORN Data
Warehouse. The ACORN Data Warehouse contains elec-
tronic medical record, billing, and patient reported out-
come data from 13 community oncology practices. Data
are extracted electronically, refreshed weekly, and used as
source data for cancer research. Medical charts were sub-
sequently reviewed to determine final study eligibility. The
final study sample was drawn from patients in seven
affiliated practices. All study procedures were approved by
IntegReview, a commercial IRB in Austin, TX.
Patients were eligible if they were at least 18 years of
age, had a confirmed diagnosis of stage IV colorectal
cancer, had experienced at least one disease progression
after diagnosis with mCRC, and received second-line
treatment with a qualifying regimen. Qualifying regi-
mens were those that included bevacizumab, cetuximab,
or chemotherapy alone without monoclonal antibodies.
We considered regimens that included panitumumab,
but the sample of patients who received second-line
panitumumab was too small for meaningful comparison.
Eligibility also required that patients had completed at
least one Patient Care Monitor (PCM) assessment,
described further below, during the period in which they
were receiving second-line treatment for mCRC.
Primary study endpoint
The primary study endpoint was patient reported out-
comes as indicated by the PCM assessment. This
included individual PCM items such as ‘rash,’ ‘dry skin,’
‘Itching,’ ‘nail changes,’ ‘nausea’, ‘vomiting,’ ‘diarrhea,’ and
‘burning sensation in hands or feet.’ It also included
PCM index scores, described below. Although other
symptoms were of interest for the study, the range of
items under consideration was limited by those available
as part of the PCM. The focus of reporting in this paper
is the individual PCM items that describe specific pa-
tient symptoms, listed above.
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that assesses physical symptoms, psychological symp-
toms and physical functioning, and asks patients to rate
the severity of symptoms on an 11 point (0 to 10)
Likert-type scale, where higher scores reflect more severe
symptoms. The PCM is administered via touch screen
tablet personal computer as a routine part of care at par-
ticipating community oncology practices. In addition to
scores on individual PCM items, the PCM produces stan-
dardized index scores (T scores) for six screening scales in
which higher scores denote more severe symptoms. The
indices are: General Physical Symptoms, Treatment Side
Effects, Despair and Depression, Acute Distress, Impaired
Ambulation, and Impaired Performance. The PCM has
been shown to be valid for assessing symptom burden and
HRQoL in cancer patients and has been used in a number
of studies [23-27]. The focus of this study was on symp-
tom burden.
Other measures
Demographic characteristics included age, gender, ethni-
city, body mass index, and geographic location. Clinical
characteristics included performance status, primary CRC
site, sites of metastases, tumor histology, KRAS status if
available, and the presence vs. absence of documented evi-
dence for KRAS testing prior to the start of second-line
treatment. Treatment characteristics included first and
second-line chemotherapy and/or targeted therapy regi-
mens, including duration of first-line therapy.
Statistical methods
The underlying populations of patients treated with
bevacizumab, cetuximab, or chemotherapy alone from
which the sample was drawn were not of equal size;
resulting samples in each treatment group were there-
fore expected to be unequal. In particular, we were aware
that more patients with bevacizumab experience were
available, and planned for a larger sample in this group to
provide increased statistical power for group comparisons.
Descriptive statistics were generated for all demographic,
disease, and treatment characteristics. Frequencies and
percentages were generated for categorical variables and
the mean, standard deviation, median, minimum, and
maximum were generated for continuous variables. Chi-
square tests of independence and Fisher’s Exact test were
used to compare groups across levels of categorical vari-
ables. T tests and analysis of variance were used to com-
pare groups on continuous variables.
Linear mixed models were employed to examine change
in PCM endpoints over time during the second-line period,
across Bevacizumab vs. Cetuximab vs. Chemotherapy Only
groups, with the Bevacizumab group defined as the refer-
ence for group comparison. Models employed restricted
maximum likelihood estimation, with random interceptand random slope for regression of PCM endpoints
on interval since starting second-line chemotherapy.
Methods generally followed those reported by Cnaan
and Little [28,29].
Models included as predictors the interval in days
between the start of second-line treatment and the PCM
survey (Interval), the treatment group (Group), and the
interaction of these two terms. These were included in the
models irrespective of statistical significance. Each model
also considered the following predictors for inclusion in
the model: race group, age at start of second-line therapy,
duration in days of first-line therapy, body mass index,
whether the patients were receiving chemotherapy or tar-
geted therapy at the time of the PCM survey, first-line
treatment regimen as containing oxaliplatin vs. irinotecan
vs. neither, and second-line chemotherapy regimen as
containing oxaliplatin vs. irinotecan vs. neither.
A second set of models were generated which addition-
ally controlled for baseline PCM values. Baseline values
were defined as the PCM score closest in time to the start
date of second-line therapy, and within 14 days of the start
of second-line therapy. Only patients with a qualifying
baseline value were included in this additional analysis. All
statistical tests were interpreted at alpha = .05, two tailed,
and no adjustment was made for multiple comparisons.
Results
Sample development
A total of 696 potentially eligible patients were identified,
14.7% of whom on review did not have metastatic disease,
or did not have CRC. Primary reasons for exclusion in the
remaining potentially eligible subjects included no evi-
dence of disease progression after diagnosis with mCRC
(17.4%), initiating second-line therapy prior to January 1,
2007 (23.3%) and insufficient PCM data (10.5%). A total of
182 patients met all eligibility criteria, and represented the
final study sample. Figure 1 shows sample development.
Study population
The sample was largely Caucasian (67.6%) with a mean age
of 62.0 (SD=12.6) years. About half of the sample was fe-
male (51.1%). Three quarters of patients resided in the
southern United States. By definition, all patients had stage
IV disease. The most common primary sites of disease
were sigmoid colon, cecum, and ascending colon. More
than 90% of patients had adenocarcinoma. The predomin-
ant sites of metastasis were liver (65.4%), lung (46.7%), and
the peritoneum (23.6%). KRAS test status was unavailable
in 55% of patients, primarily due to the fact that 52% of
patients initiated second-line therapy prior to June 2008.
Among those patients where KRAS testing was known to
occur (N=44), 45.5% had mutant results. There were no
significant differences in any of the demographic or clinical
characteristics across the three regimen groups.
Figure 1 Sample development.
Walker et al. BMC Research Notes 2012, 5:314 Page 4 of 10
http://www.biomedcentral.com/1756-0500/5/314Fifty eight percent of the sample used a second-line
regimen containing bevacizumab, 21% used a second-
line regimen containing cetuximab, and 21% used a
chemotherapy regimen that did not include a monoclonal
antibody. Note, however, that the study sample was a
convenience sample—patients were not randomly selected.
The distribution of second-line regimens observed in this
sample is therefore not assumed to reflect the population
distribution of second-line regimens.
The mean duration of first-line therapy across all
groups was 212.5 days (SD= 162 days), and this did not
significantly vary across second-line regimen group
(p = .136). The mean duration of second-line therapy
across all groups was 144.7 days (SD= 116.4), but 17
patients had not finished second-line therapy at the time
of data collection. Time to event analysis of the duration
of second-line therapy was therefore conducted, to pro-
vide an unbiased estimate of the duration. This analysis
showed the median duration of second-line therapy to
be 124 days (Chemotherapy Only: 100 days, Cetuximab:
113 days, Bevacizumab: 136 days). A log rank test com-
paring duration across second-line treatment groupsshowed the group differences in duration of second-line
therapy to be statistically significant (p = .0399).
Cetuximab patients were more likely than expected
to have received an irinotecan-based regimen (χ2
(186,2) = 8.765, p = .0129). Nearly all patients who
received an oxaliplatin-based regimen were in the
Bevacizumab group, with about half of Bevacizumab
patients receiving oxaliplatin, compared with about
11% in the combined Chemotherapy Only and Cetuximab
groups (χ2 (186,2) = 31.004, p < .001). Bevacizumab patients
were also much more likely to have used 5-FU based regi-
mens (χ2 (186,2) = 21.548, p < .001). There was no signifi-
cant difference in the rate at which patients received
capecitabine as part of their regimen.
Additional detail on the demographic, clinical and
treatment characteristics of the population, by treatment
group, are reported in Tables 1 and 2.
Patient care monitor assessment
There were 1236 valid PCM assessments available from
the 182 patients in the study. Baseline scores were avail-
able for 90.6% of patients (n = 165), who provided a total
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for baseline symptom scores.
Moderate to severe symptomatology
Many patients experienced moderate to severe symp-
toms, defined by PCM item scores ≥ 4, at some point
during second-line therapy. Fatigue was the most com-
mon, occurring at moderate to severe levels in 67% of
patients. The Cetuximab group reported a significantly
higher rate of moderate to severe dry skin (p < .0001),
itching (p = .0028), and rash (p < .0001), with rash rates
of 60.5% in the Cetuximab group vs. 7.5% in the Bevaci-
zumab group. Patients on Chemotherapy Only had a
higher rate of moderate to severe nausea (p = .0485) than
the Bevacizumab group, and tended to have a higher rateTable 1 Demographic & clinical characteristics by treatment g
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Mean (SD) 26.3 (6.2)
Disease Stage, n (%)





Text indication of impairment 4 (10.5%)
No text indication of impairment 16 (42.1%)




Small intestine 0 (0%)
Other 16 (42.1%)
Not documented 0 (0%)
* Patients may be represented on more than one row.of physical pain (p = .0564) than the Bevacizumab group.
The Cetuximab group tended to have a lower rate of
moderate to severe problems with sweating than did the
Bevacizumab group (p = .0637). Groups did not differ
significantly on other symptoms.
Linear mixed models analysis of PCM items
Baseline analyses
Linear mixed models were run twice, with one set of mod-
els controlling for baseline scores and a second set of
models not controlling for baseline scores. Treatment
group was significant in almost all of the models that did
not control for baseline scores. However, after inclusion of
baseline scores, those results changed notably as baseline
symptom burden scores were the strongest predictor ofroup
Cetuximab N = 38 BevacizumabN = 106 Total N = 182
14 (36.8%) 56 (52.8%) 93 (51.1%)
64.6 (11.2) 61.5 (12.3) 62.0 (12.6)
3 (7.9%) 3 (2.8%) 10 (5.5%)
2 (5.3%) 4 (3.8%) 6 (3.3%)
28 (73.7%) 83 (78.3%) 138 (75.8%)
5 (13.2%) 16 (15.1%) 28 (15.4%)
26 (68.4%) 71 (67.0%) 123 (67.6%)
12 (31.6%) 35 (33.0%) 59 (32.4%)
38 (100%) 106 (100%) 182 (100%)
28.9 (5.2) 26.9 (5.4) 27.2 (5.6)
38 (100%) 106 (100%) 182 (100%)
10 (26.3%) 19 (17.9%) 37 (20.3%)
6 (15.8%) 19 (17.9%) 33 (18.1%)
3 (7.9%) 3 (2.8%) 8 (4.4%)
2 (5.3%) 14 (13.2%) 20 (11.0%)
17 (44.7%) 51 (48.1%) 84 (46.2%)
24 (63.2%) 71 (67.0%) 119 (65.4%)
21 (55.3%) 50 (47.2%) 85 (46.7%)
6 (15.8%) 28 (26.4%) 43 (23.6%)
0 (0%) 4 (3.8%) 4 (2.2%)
15 (39.5%) 47 (44.3%) 78 (42.9%)
0 (0%) 1 (0.9%) 1 (0.5%)
Table 2 Treatment characteristics by second-line treatment group
Chemotherapy only
N = 38
Cetuximab N = 38 Bevacizumab N = 106 Total N = 182
Regimen used in 1st line therapy, n (%)
Oxaliplatin based 5 (13%) 4 (11%) 54 (51%) 63 (35%)
Irinotecan based 21 (55%) 28 (74%) 40 (38%) 89 (49%)
Neither Oxaliplatin nor Irinotecan based 12 (32%) 6 (16%) 12 (11%) 30 (16%)
Regimen used in 2nd line therapy, n (%)
5-FU 0 (0.0%) 0 (0.0%) 1 (0.9%) 1 (0.5%)
5-FU / AMG 706 / Irinotecan / Leucovorin 1 (2.6%) 0 (0.0%) 0 (0.0%) 1 (0.5%)
5-FU / Gamma Interferon / Irinotecan / Leucovorin 0 (0.0%) 0 (0.0%) 1 (0.9%) 1 (0.5%)
5-FU / Gamma Interferon / Leucovorin 2 (5.3%) 0 (0.0%) 0 (0.0%) 2 (1.1%)
5-FU / Interferon / Leucovorin 2 (5.3%) 0 (0.0%) 0 (0.0%) 2 (1.1%)
5-FU / Irinotecan / Leucovorin 6 (15.8%) 13 (34.2%) 29 (27.4%) 48 (26.4%)
5-FU / Irinotecan / Leucovorin / Oxaliplatin 0 (0.0%) 0 (0.0%) 5 (4.7%) 5 (2.7%)
5-FU / Irinotecan / Leucovorin / Oxaliplatin / Capecitabine 0 (0.0%) 0 (0.0%) 2 (1.9%) 2 (1.1%)
5-FU / Irinotecan / Leucovorin / Capecitabine 2 (5.3%) 0 (0.0%) 4 (3.8%) 6 (3.3%)
5-FU / Leucovorin 2 (5.3%) 1 (2.6%) 3 (2.8%) 6 (3.3%)
5-FU / Leucovorin / Oxaliplatin 3 (7.9%) 3 (7.9%) 38 (35.8%) 44 (24.2%)
5-FU / Leucovorin / Oxaliplatin / Capecitabine 0 (0.0%) 0 (0.0%) 1 (0.9%) 1 (0.5%)
Bevacizumab Only 0 (0.0%) 0 (0.0%) 2 (1.9%) 2 (1.1%)
Cetuximab Only 0 (0.0%) 4 (10.5%) 0 (0.0%) 4 (2.2%)
Floxuridine / Irinotecan 1 (2.6%) 0 (0.0%) 0 (0.0%) 1 (0.5%)
Irinotecan 11 (28.9%) 13 (34.2%) 3 (2.8%) 27 (14.8%)
Irinotecan / Oxaliplatin / Capecitabine 0 (0.0%) 0 (0.0%) 1 (0.9%) 1 (0.5%)
Irinotecan / Capecitabine 0 (0.0%) 2 (5.3%) 3 (2.8%) 5 (2.7%)
Oxaliplatin / Capecitabine 2 (5.3%) 1 (2.6%) 7 (6.6%) 10 (5.5%)
Capecitabine 6 (15.8%) 1 (2.6%) 6 (5.7%) 13 (7.1%)
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(all p’s < .0001 except for Rash, p = .0013).
Rash
As evidenced in Figure 2, patients in the Bevacizumab
group had significantly (p < .0001) lower (better) Rash
scores than did patients in the Cetuximab group and
nominally lower scores than patients in the Chemotherapy
Only group. Rash scores in the Cetuximab group fell fas-
ter than those in the Bevacizumab group (p= .019), albeit
from a higher level. It should be noted that scores in the
Bevacizumab group were near enough to zero that they
had little room to fall. Although baseline rash scores sig-
nificantly predicted rash scores during second-line therapy
(p= .0013), membership in the Cetuximab group was a
very strong predictor. Longer duration of first-line therapy
was associated with less severe rash symptoms (p= .0375).
Patients on either irinotecan or oxaliplatin had less severe
symptoms (p= .0001, p = .0005, respectively) than patients
on neither agent.Dry skin
There was a significant effect of Group (p< .0013), Interval
(p = .01), and the interaction of the two (p= .0128) on Dry
Skin scores (Figure 3), controlling for baseline. This sug-
gests that Bevacizumab and Chemotherapy Only patients
had low and stable scores whereas Cetuximab patients had
Dry Skin scores that were significantly higher than the
Bevacizumab group (p = .0008), and that also were
changing (worsening) at a rate significantly different from
the Bevacizumab group (p= .0037). Baseline scores were
also a significant predictor in this model. Baseline adjusted
scores for the Chemotherapy Only group were compar-
able to those of the Bevacizumab group whereas, when
not controlled, they appeared significantly elevated. The
implication of this result is that Chemotherapy Only
patients may be more likely than Bevacizumab patients to
enter therapy with elevated Dry Skin ratings. For those
who do, elevated scores may persist. However, it is the ele-
vated baseline scores that drive elevated scores during
second-line therapy, not their group membership. In
Figure 2 Linear mixed model of rash scores controlling for baseline.
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patients receiving bevacizumab, regardless of whether
or not we controlled for baseline values.
Itching
Itching scores tended to be stable across treatment
groups (Figure 4). Baseline scores were a significant pre-
dictor in this model (p < .0001). Controlling for baseline
scores, the Bevacizumab group scored significantly lower
(better) than the Cetuximab group (p = .0002), and no
different from the Chemotherapy Only group. As in the
model for Dry Skin, baseline adjusted scores for the
Chemotherapy Only group were comparable to those ofFigure 3 Linear mixed model of dry skin scores controlling for baselinthe Bevacizumab group, but scores not adjusted for
baseline were elevated compared to the Bevacizumab
group. As with the analysis of Dry Skin, the implica-
tion is that the baseline scores of Chemotherapy Only
patients, and not their group membership, dictated
scores during second-line therapy. In contrast, for the
Cetuximab patients, their membership in the Cetuximab
group predicted higher scores during second-line chemo-
therapy, independent of their baseline scores.
Nail changes
There was a significant main effect of Interval (p= .0292),
and a near significant interaction of Group with Intervale.
Figure 4 Linear mixed model of itching scores controlling for baseline.
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therapy Only groups basically had stable Nail Change
scores that did not significantly differ, controlling for base-
line. Conversely the Cetuximab group had scores that
were increasing, representing a rate of change over time
that was significantly greater than that of the Bevacizumab
group (p= .0182). Baseline scores positively predicted
scores during treatment (p < .0001).
Nausea
There was a significant but modest main effect of Interval
(p = .0188), in which Nausea scores improved slightly over
time. The effect represented less than 1 point improve-
ment over a one year period with little notable difference
among groups. Baseline scores did significantly predict
Nausea scores over time during second-line treatment
(p < .0001). There also was a small effect associated with
duration of first-line treatment (p= .022), in which longer
first-line treatment (e.g. 2 months) was associated with
somewhat milder (0.1 point improvement) nausea symp-
toms during second-line therapy.
Vomiting
There was a significant but slight main effect of Interval
(p = .0007), with Vomiting scores decreasing (improving)
over time. However, the effect was very small (e.g. a 0.1
point improvement over a 5 month period, well short of a
clinically significant effect), with very mild symptoms
overall. There was no significance in the main effect of
Group, or in the interaction of Group and Interval. Base-
line scores strongly predicted Vomiting scores during
treatment (p< .0001).Diarrhea
There was a significant effect of Interval (p < .0001), con-
trolling for baseline, with scores improving over time.
There was no significant main effect of Group, and no
significant interaction between Interval and Group.
Burning sensation in hands & feet
There were no significant main effects or interaction be-
tween Group and Interval on Scores for Burning Sensation
in Hands & Feet. Baseline scores did predict scores during
second-line but with or without control of baseline, scores
were relatively low, indicating mild symptoms, and rela-
tively stable scores.
PCM index scores
Models assessing group differences on PCM index scores
were also examined. In general, due to the composite
nature of these measures, and the specificity of effects
described in the foregoing section, any group differences
were washed out on these endpoints. As noted earlier, the
individual PCM items were the primary focus of the
investigation.
Discussion
This study examined retrospectively collected medical
record data, and repeated symptom burden assessments,
from CRC patients with metastatic disease treated in the
second-line setting with regimens containing Bevacizumab,
Cetuximab, or Chemotherapy Only at seven community
oncology practices in the United States (U.S.).
The results suggest that baseline symptom burden
scores are the strongest single predictor of second-line
Walker et al. BMC Research Notes 2012, 5:314 Page 9 of 10
http://www.biomedcentral.com/1756-0500/5/314symptom burden across the items measured in this
study. However, after controlling for baseline symptom
scores, the data suggest that patients on a Bevacizumab
containing regimen tended to have more stable and less
severe symptoms as measured by PCM items than
patients on a Cetuximab containing regimen, and than
patients on Chemotherapy Only in several areas.
This study adds to the literature in several ways. By
assessing key symptoms with repeated assessments, this
study was able to characterize symptom burden specific-
ally during second-line therapy, after patients had received
prior treatment and experienced disease progression. The
study was able to directly compare symptom burden in
key areas across regimens that included two widely used
biologics, and across regimens that included chemother-
apy only without monoclonal antibodies. The study was
also able to show that some symptoms present at initi-
ation of second-line therapy persist, and that symptoms
assumed to reflect treatment group effects may be attribut-
able to group differences in symptom burden at initiation
of second-line therapy. The study was unable to iden-
tify obvious demographic or clinical differences between
patients in the treatment groups. Given that there were
group differences in self-reported symptom burden at
start of second-line therapy, this suggests that these dif-
ferences may not be easily identifiable other than by
self-report, or that they arose during first-line therapy.
Clinicians should be aware of both possibilities.
Elevated dermatological symptoms during second-line
therapy were observed in both the Cetuximab and
Chemotherapy Only groups, but were substantially
explained by baseline scores for the Chemotherapy Only
group. This was not true of the Cetuximab group, how-
ever. The data do not reveal why patients with elevated
scores at baseline had these elevated scores—there were
no identifiable differences across treatment groups in first-
line regimen, or in the duration of first-line therapy. Re-
gardless, the data do suggest that patients in the Chemo-
therapy Only group who did not have elevated rash and
dry skin symptoms at baseline tended not to report such
problems during second-line therapy, and that this claim
is not supported for the Cetuximab group.
Although PCM index scores may be less sensitive to spe-
cific effects due to their composite nature, previous re-
search has shown them to be sensitive endpoints in other
cancer populations [26,30,31]. As noted, these were not the
focus of the analysis, but given findings in prior research,
the absence of findings for PCM index scores was some-
what unexpected.
In interpreting these findings, the following factors
should be considered. First, although data were collected
from a number of geographically dispersed oncology clinics
in the U.S., the study used a convenience sample that may
differ in unknown ways from the underlying population.Also, the observational nature of this research involved
comparison of existing groups, with the possibility that
there were pre-existing group differences related to the
study outcomes. For example, it is possible that patients
treated with Bevacizumab may have had some unknown se-
lection factor operating such that patients with fewer pre-
existing risk factors for skin related toxicities were also
more likely to receive Bevacizumab than either Cetuximab
or Chemotherapy Only. In this and other ways, selection
bias may therefore have affected the direction and magni-
tude of group differences observed. A further limitation is
that the comparison groups were unequal in sample size
with the Bevacizumab group having 106 cases compared to
the Cetuximab and Chemotherapy only groups with 38
cases each. This reduced the statistical power of compari-
sons among groups relative to a balanced study design. Fi-
nally, we examined patients with mCRC treated in
community practice settings. Results may therefore not
generalize to patients with other diseases, with disease at
other stages, and to patients treated in other settings.
Conclusions
The biggest predictor of second-line symptom burden
is the symptom burden observed at the end of the
first-line regimen. Patients receiving a second-line therapy
for mCRC which contained bevacizumab reported fewer
treatment-related symptoms as compared to patients re-
ceiving a regimen containing cetuximab.
Clinical practice points
Treatment side effects common to systemic cancer ther-
apy may be present at the start of second-line treatment
of mCRC. The severity of these symptoms is predictive of
the severity of symptoms patients will self-report as
present during the course of second-line therapy. Al-
though there are differences in the pattern of symptoms
patients may experience across regimens and with differ-
ent biologic therapies, differences in side effect profile
across regimens during second-line mCRC may reflect
baseline differences in symptom burden. These symptoms
may be attributable to the first-line regimens received, and
may not be evident other than through patient self-report.
Additional discussion of symptom severity with patients
may be useful in this regard.
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